- Home
- FTLF vs ACRS Comparison
FTLF vs ACRS Comparison
Compare FTLF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTLF
- ACRS
- Stock Information
- Founded
- FTLF 2005
- ACRS 2012
- Country
- FTLF United States
- ACRS United States
- Employees
- FTLF N/A
- ACRS N/A
- Industry
- FTLF Medicinal Chemicals and Botanical Products
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- FTLF Health Care
- ACRS Health Care
- Exchange
- FTLF Nasdaq
- ACRS Nasdaq
- Market Cap
- FTLF 149.3M
- ACRS 165.7M
- IPO Year
- FTLF N/A
- ACRS 2015
- Fundamental
- Price
- FTLF $16.61
- ACRS $1.87
- Analyst Decision
- FTLF Strong Buy
- ACRS Strong Buy
- Analyst Count
- FTLF 2
- ACRS 9
- Target Price
- FTLF $23.00
- ACRS $9.25
- AVG Volume (30 Days)
- FTLF 21.9K
- ACRS 1.5M
- Earning Date
- FTLF 08-14-2025
- ACRS 08-07-2025
- Dividend Yield
- FTLF N/A
- ACRS N/A
- EPS Growth
- FTLF N/A
- ACRS N/A
- EPS
- FTLF 0.80
- ACRS N/A
- Revenue
- FTLF $63,053,000.00
- ACRS $16,789,000.00
- Revenue This Year
- FTLF $4.72
- ACRS N/A
- Revenue Next Year
- FTLF $6.61
- ACRS $8.11
- P/E Ratio
- FTLF $20.76
- ACRS N/A
- Revenue Growth
- FTLF 3.91
- ACRS N/A
- 52 Week Low
- FTLF $9.83
- ACRS $1.05
- 52 Week High
- FTLF $17.75
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- FTLF 67.76
- ACRS 75.14
- Support Level
- FTLF $14.19
- ACRS $1.58
- Resistance Level
- FTLF $16.81
- ACRS $1.77
- Average True Range (ATR)
- FTLF 0.92
- ACRS 0.11
- MACD
- FTLF 0.34
- ACRS 0.02
- Stochastic Oscillator
- FTLF 95.64
- ACRS 94.25
About FTLF FitLife Brands Inc.
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.